A clinical trial to study the effects of the drug metformin as a cream for patients with melasma

An interventional study to evaluate the efficacy and safety of topical metformin in the treatment of melasma at a tertiary care center - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070444

Enrollment

Registered

2024-07-10

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Metformin cream: Once daily application on the face at night for 12 weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: ADULT MALES OR FEMALES WITH A CLINICAL DIAGNOSIS OF MELASMA

Exclusion criteria

Exclusion criteria: Age less than 18 years or more than 80 years. Pregnant. Lactating. Patients with a history of photosensitivity disorders. Patients on medications known to cause hyperpigmentation or photosensitivity. Patients on immunosuppressants . Patients with facial pigmentation caused by conditions other than melasma.

Design outcomes

Primary

Measure	Time frame
Percentage of patients with reduction in modified melasma area and severity indexTimepoint: 12 weeks	—

Secondary

Measure	Time frame
Percentage of patients with increase in patient satisfaction scale.Timepoint: 12 weeks;Percentage of patients with reduction in dermoscopy scoreTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactAnu Sarah Philip

Bangalore Medical College and Research Institute

amritahongalleo@gmail.com8921538863

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026